KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
2023-05-19
引进/卖出免疫疗法临床研究AACR会议
PITTSBURGH, May 19, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
VET3-TGI is based on KaliVir's unique Vaccinia Enhanced Template (VET™) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and enhance intravenous delivery and spread. Modifications grant VET3-TGI the expression of CXCR3, IL-12 and a TGF-β inhibitorTGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and the overcoming of local immunosuppressive activity.
The functionality and therapeutic activity of VET3-TGI were tested in multiple models, and the mechanism of action and toxicity pro assessed. VET3-TGI was compared to control virus in three pre-clinical in vivo tumor models, and demonstrated potent therapeutic activity, including 100% complete responses, even at several logs below equivalent clinical doses and in the presence of pre-existing anti-viral immunity. Profound changes in the tumor microenvironment (TME) were observed in VET3-TGI treated mice, including polarization to a type-1 immune response and recruitment of cytotoxic T cells. Analysis of gene expression profiles revealed that VET3-TGI treatment was associated with a dramatic increase in type-1 inflammatory chemokines, and a concomitant decrease in the expression of TGFβ1-associated genes that are involved with immuno-suppression. Compared to control virus-treated mice, VET3-TGI showed improved delivery to tumors following systemic administration, as well as reduced systemic toxicity.
"This new in vivo data is very encouraging and is a further validation of VET3-TGI as our lead pre-clinical candidate," said Stephen Thorne, PhD, CSO and co-founder of KaliVir. "These results build upon our already robust in vitro data as we expand into the next phase to develop a human version of the virus for efficacy and toxicology testing."
About KaliVir Immunotherapeutics, Inc.
KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform, Vaccinia Enhanced Template "VET" Platform, that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. VET™ platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients' immune systems and modify the tumor microenvironment. KaliVir's oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET™ platform. In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVirKaliVir's initial lead clinical candidate VET2-L2 oncolytic vaccinia virus. KaliVirKaliVir is currently advancing multiple therapeutic candidates toward the clinic. For more information, please visit .
Media Contact:
Michael Falcone
MacDougall Advisors
MFalcone@macdougall.bio
781-591-3448
View original content to download multimedia:
SOURCE KaliVir Immunotherapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。